Kun-Yu Teng1, Anthony G Mansour1, Zheng Zhu1, Zhiyao Li1, Lei Tian1, Shoubao Ma1, Bo Xu1, Ting Lu1, Hanyu Chen1, David Hou1, Jianying Zhang2, Saul J Priceman3, Michael A Caligiuri4, Jianhua Yu5. 1. Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Los Angeles, California. 2. Department of Computational and Quantitative Medicine, City of Hope National Medical Center, Los Angeles, California. 3. Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Los Angeles, California; City of Hope Comprehensive Cancer Center, Los Angeles, California. 4. Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Los Angeles, California; Hematologic Malignancies Research Institute, City of Hope National Medical Center, Los Angeles, California; City of Hope Comprehensive Cancer Center, Los Angeles, California. Electronic address: mcaligiuri@coh.org. 5. Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Los Angeles, California; Department of Immuno-Oncology, Beckman Research Institute, City of Hope Comprehensive Cancer Centre, Los Angeles, California; Hematologic Malignancies Research Institute, City of Hope National Medical Center, Los Angeles, California; City of Hope Comprehensive Cancer Center, Los Angeles, California. Electronic address: jiayu@coh.org.
Abstract
BACKGROUND & AIMS: Pancreatic cancer (PC) is the third leading cause of cancer-related death with a 5-year survival rate of approximately 10%. It typically presents as a late-stage incurable cancer and chemotherapy provides modest benefit. Here, we demonstrate the feasibility, safety, and potency of a novel human natural killer (NK) cell-based immunotherapy to treat PC. METHODS: The expression of prostate stem cell antigen (PSCA) was evaluated in primary PC at messenger RNA and protein levels. The processes of retroviral transduction, expansion, activation, and cryopreservation of primary human NK cells obtained from umbilical cord blood were optimized, allowing us to develop frozen, off-the-shelf, allogeneic PSCA chimeric antigen receptor (CAR) NK cells. The safety and efficacy of PSCA CAR NK cells also expressing soluble (s) interleukin 15 (PSCA CAR_s15 NK cells) were evaluated in vitro and in vivo. RESULTS: PSCA was elevated in primary human PC compared with the adjacent or other normal tissues. PSCA CAR_s15 NK cells displayed significant tumor-suppressive effects against PSCA(+) PC in vitro before and after 1 cycle of freeze-thaw. The viability of frozen PSCA CAR_s15 NK cells persisted more than 90 days in vivo after their last infusion and significantly prolonged the survival of mice engrafted with human PC. CONCLUSIONS: PSCA CAR_s15 NK cells showed therapeutic efficacy in human metastatic PC models without signs of systematic toxicity, providing a strong rationale to support clinical development.
BACKGROUND & AIMS: Pancreatic cancer (PC) is the third leading cause of cancer-related death with a 5-year survival rate of approximately 10%. It typically presents as a late-stage incurable cancer and chemotherapy provides modest benefit. Here, we demonstrate the feasibility, safety, and potency of a novel human natural killer (NK) cell-based immunotherapy to treat PC. METHODS: The expression of prostate stem cell antigen (PSCA) was evaluated in primary PC at messenger RNA and protein levels. The processes of retroviral transduction, expansion, activation, and cryopreservation of primary human NK cells obtained from umbilical cord blood were optimized, allowing us to develop frozen, off-the-shelf, allogeneic PSCA chimeric antigen receptor (CAR) NK cells. The safety and efficacy of PSCA CAR NK cells also expressing soluble (s) interleukin 15 (PSCA CAR_s15 NK cells) were evaluated in vitro and in vivo. RESULTS: PSCA was elevated in primary human PC compared with the adjacent or other normal tissues. PSCA CAR_s15 NK cells displayed significant tumor-suppressive effects against PSCA(+) PC in vitro before and after 1 cycle of freeze-thaw. The viability of frozen PSCA CAR_s15 NK cells persisted more than 90 days in vivo after their last infusion and significantly prolonged the survival of mice engrafted with human PC. CONCLUSIONS: PSCA CAR_s15 NK cells showed therapeutic efficacy in human metastatic PC models without signs of systematic toxicity, providing a strong rationale to support clinical development.
Authors: Janelle A Olson; Dennis B Leveson-Gower; Saar Gill; Jeanette Baker; Andreas Beilhack; Robert S Negrin Journal: Blood Date: 2010-03-16 Impact factor: 22.113
Authors: Prasad S Adusumilli; Leonid Cherkassky; Jonathan Villena-Vargas; Christos Colovos; Elliot Servais; Jason Plotkin; David R Jones; Michel Sadelain Journal: Sci Transl Med Date: 2014-11-05 Impact factor: 17.956
Authors: Anirban Maitra; N Volkan Adsay; Pedram Argani; Christine Iacobuzio-Donahue; Angelo De Marzo; John L Cameron; Charles J Yeo; Ralph H Hruban Journal: Mod Pathol Date: 2003-09 Impact factor: 7.842
Authors: Avery D Posey; Robert D Schwab; Alina C Boesteanu; Catharina Steentoft; Ulla Mandel; Boris Engels; Jennifer D Stone; Thomas D Madsen; Karin Schreiber; Kathleen M Haines; Alexandria P Cogdill; Taylor J Chen; Decheng Song; John Scholler; David M Kranz; Michael D Feldman; Regina Young; Brian Keith; Hans Schreiber; Henrik Clausen; Laura A Johnson; Carl H June Journal: Immunity Date: 2016-06-21 Impact factor: 31.745
Authors: John P Murad; Dileshni Tilakawardane; Anthony K Park; Lupita S Lopez; Cari A Young; Jackson Gibson; Yukiko Yamaguchi; Hee Jun Lee; Kelly T Kennewick; Brenna J Gittins; Wen-Chung Chang; Chau P Tran; Catalina Martinez; Anna M Wu; Robert E Reiter; Tanya B Dorff; Stephen J Forman; Saul J Priceman Journal: Mol Ther Date: 2021-02-27 Impact factor: 12.910
Authors: Saul J Priceman; Ethan A Gerdts; Dileshni Tilakawardane; Kelly T Kennewick; John P Murad; Anthony K Park; Brook Jeang; Yukiko Yamaguchi; Xin Yang; Ryan Urak; Lihong Weng; Wen-Chung Chang; Sarah Wright; Sumanta Pal; Robert E Reiter; Anna M Wu; Christine E Brown; Stephen J Forman Journal: Oncoimmunology Date: 2017-10-16 Impact factor: 8.110
Authors: J Chu; Y Deng; D M Benson; S He; T Hughes; J Zhang; Y Peng; H Mao; L Yi; K Ghoshal; X He; S M Devine; X Zhang; M A Caligiuri; C C Hofmeister; J Yu Journal: Leukemia Date: 2013-09-26 Impact factor: 11.528
Authors: Guang He Ran; Yu Qing Lin; Lei Tian; Tao Zhang; Dong Mei Yan; Jian Hua Yu; You Cai Deng Journal: Signal Transduct Target Ther Date: 2022-06-29
Authors: Ting Lu; Rui Ma; Wenjuan Dong; Kun-Yu Teng; Daniel S Kollath; Zhiyao Li; Jinhee Yi; Christian Bustillos; Shoubao Ma; Lei Tian; Anthony G Mansour; Zhenlong Li; Erik W Settles; Jianying Zhang; Paul S Keim; Bridget M Barker; Michael A Caligiuri; Jianhua Yu Journal: Nat Commun Date: 2022-05-11 Impact factor: 17.694